Hypermarcas (OTCMKTS:HYPMY) Short Interest Down 99.5% in May

Hypermarcas (OTCMKTS:HYPMY) was the recipient of a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 16 shares, a decrease of 99.5% from the May 14th total of 3,352 shares. Based on an average daily trading volume, of 88,307 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Hypermarcas to a “hold” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Hypermarcas has an average rating of “Buy”.

Hypermarcas Stock Performance

Shares of HYPMY traded up $0.06 during mid-day trading on Thursday, reaching $4.04. The company had a trading volume of 4,622 shares, compared to its average volume of 24,748. Hypermarcas has a 52-week low of $3.71 and a 52-week high of $5.50. The company has a quick ratio of 0.84, a current ratio of 1.27 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $2.84 billion, a P/E ratio of 8.42 and a beta of 0.70. The stock has a 50 day moving average of $4.51 and a two-hundred day moving average of $4.47.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share for the quarter. The company had revenue of $383.13 million during the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%. On average, analysts expect that Hypermarcas will post 0.53 earnings per share for the current year.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.